New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

GALR3 Polyclonal Antibody, FITC Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Pig
  • Horse
Overview
Catalog # bs-11528R-FITC
Product Name GALR3 Polyclonal Antibody, FITC Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Pig, Horse
Specifications
Conjugation FITC
Host Rabbit
Source KLH conjugated synthetic peptide derived from human GALR3
Immunogen Range 1-100/368
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 8484
Subcellular location Cell membrane
Synonyms GAL 3R; GAL R3; GAL3 R; GAL3-R; GAL3R; Galanin receptor 3; Galanin receptor-3; Galanin receptor family member 3; Galanin receptor type 3; GALN R3; GALNR 3; GALNR3; GALR 3; GALR-3; Galr3; GALR3_HUMAN.
Background GALR3 a 368 and 370 amino acid protein in human and rat, respectively, belongs to a family of G protein-coupled receptors that bind the neuropeptide galanin, which is distributed throughout the central and peripheral nervous system, the pituitary gland, the gastrointestinal tract and in the endocrine and exocrine pancreas. GALR3 mRNA is widely distributed, but expressed at low abundance. In human, GALR3 mRNA is highly expressed in the hypothalamus, pituitary and testis, and is expressed to a lesser extent in adrenal gland and pancreas. Rat and human GALR3 co-express with potassium channel subunits GIRK1 and GIRK4. Like GALR1, GALR3 signaling pathways lead to the inhibition of adenylate cyclase and to the activation of potassium channels, which are linked to the regulation of neurotransmitter release. Binding of galanin to galanin receptors results in increased feeding, impaired learning, enhanced opiate analgesia and decreased opiate place preference.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200